New Ataluren UK Clinical Trials - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: We are delighted to inform you that PTC Therapeutics has been able to establish an extension study in the UK for their drug ataluren for patients who participated in the Phase 2b. This extension study will take place at two centres: Newcastle and London. The background to this decision by PTC Therapeutics can be found at http://www.actionduchenne.org/viewarticle?news=387 .
Secondly, PTC Therapeutics is in active communication with European regulators to run a wider confirmatory study with the aim of confirming the findings of the previous study. We look forward to welcoming PTC Therapeutics to our forthcoming annual conference where we hope there will be an opportunity to find out more about their plans.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment